Scandion Oncology A/S (STO:SCOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0226
-0.0001 (-0.44%)
May 16, 2025, 9:51 AM CET
-98.39%
Market Cap 5.33M
Revenue (ttm) n/a
Net Income (ttm) -56.32M
Shares Out 234.76M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,362,664
Average Volume 4,565,395
Open 0.0227
Previous Close 0.0227
Day's Range 0.0171 - 0.0247
52-Week Range 0.0050 - 1.5600
Beta 2.13
RSI 63.20
Earnings Date May 22, 2025

About Scandion Oncology

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol SCOL
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.